Klaus Feldmann is Vice President, Oncology Commercial Lead, MSD HH Europe and Canada. He is responsible for all commercial operations for MSD’s oncology business across Europe and Canada. Prior to this role, Klaus was VP Regional Marketing, EMEAC Oncology.
Klaus started his career in the pharmaceutical industry with AstraZeneca Germany, growing into increasingly important national and international Medical and Commercial Oncology roles. Klaus joined MSD in 2008 to lead the Oncology efforts at European level. In 2010, he moved to Global Oncology, based in UG, as the Global Brand Lead for EMEND. His next Global role was leading the commercial cooperation with Endocyte on VINTAFOLIDE.
Klaus moved to Switzerland in 2014 as the EMEAC Head of Marketing for Oncology. During his time in this role, Klaus supported the introduction of KEYTRUDA to Europe in 2015 and has since supported an expansion into many indications. Klaus is fully committed to driving executional excellence across the regional Oncology organization.
Klaus earned his PhD degree in Genetics & Molecular Biology from the Max Planck Society, Cologne and the University of Cologne, Germany.
Updated: October 2021